Twice daily Indinavir trial stopped.

A study by Merck, Inc. of twice-a-day Indinavir (Crixivan), taken with AZT and 3TC, was discontinued because of poor long-term results. The standard dose of Indinavir with AZT and 3TC produced significantly better results in lowering viral load. Other trials of twice-a-day Indinavir with Ritonavir or Nelfinavir will continue.